US judge rules against AstraZeneca in Medicare price talks challenge
01 Mar 2024
A federal judge in the US has upheld a law mandating certain drugmakers to engage in price negotiations with Medicare, dismissing a legal challenge brought by AstraZeneca.
"We are disappointed with the court's decision and the potential negative impact it will have on patients' access to future life-saving medicines," a spokesperson for AstraZeneca told FirstWord. "We believe our challenge is necessary to support and improve patients’ access to future life-saving medicines, and our rights as a company. There is a lot at stake here, and we are actively evaluating our path forward."
Judge Colm Connolly of US District Court in Delaware made his decision just as the UK drugmaker was set to respond to the US government's initial bid for the price of its diabetes treatment Farxiga, one of the first batch of drugs that are up for price negotiations with Medicare.
As part of the Biden administration's Inflation Reduction Act (IRA), the negotiation programme empowers Medicare to engage in direct price discussions with companies for specific high-cost medications. Ten medicines are subject to the first round of Medicare price talks, with the Centers for Medicare and Medicaid Services recently sending initial offers to the companies involved.
More to follow.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.